Sichuan Kelun Pharmaceutical Conducted a Audit in CHICO on April 8th, 2019. Kelun is a highly specialized innovative pharmaceutical group with annual sales revenue over 40 billion RMB, In 2017, kelun ranked 155th in China's top 500 manufacturing enterprises, and comprehensive strength ranked top three in China's pharmaceutical industry.
In 2018, with the global competitive advantage of large volume Infusions, Kelun won the individual champion award as the demonstration enterprise of manufacturing industry.
As of May 2019, Kelun ranked the second in China in terms of the number of infusion varieties applied for consistency evaluation and the number of varieties of base drugs passed the consistency evaluation.
The audit procedure included: first meeting, documentary system audit, equipments and facilities audit. Auditors affirmed the management system of CHICO, put forward valuable insights and comments, which establish the base for the further cooperation.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
